Clinical Topics   /   Oncology

VA Study Indicates That Location Matters in Colon Cancer Survival

by Annette Boyle
June 1, 2018

ALBANY, NY — More than 95,000 Americans develop colon cancer, making it the third most common cancer in the U.S., excluding skin cancers. While stage and histology are known to affect prognosis, does it matter where tumors first occur in the massive organ?

According to research released in conjunction with this weekend’s 2018 American Society of Clinical Oncology Annual Meeting, location makes a significant difference.1

A team of researchers from the Stratton VAMC and the Albany Medical College, both in Albany, NY, analyzed data from the National VA Cancer Cube Registry to detect differences in the course and characteristics of colon cancer based on tumor sidedness. They defined right-sided colon cancer as tumors that first appeared in the region from the cecum to the hepatic flexure. Left-sided colon cancer included those that originated from the splenic flexure to the rectum. Transverse cancer included all those that arose between the flexures.

The researchers identified 65,940 total cases of colon cancer diagnosed in veterans who received care at VA facilities between 2001 and 2015. Of those, they classified 30.1% as right-sided and 58.8% as left-sided colon cancers.

Right-sided colon cancer arose more frequently in women, in whom it accounted for 36.3% of cases, compared to 30.1% of cases in men. Right-sided colon cancer also represented the majority (51.8%) of cases in patients over the age of 70, while about one-third of older patients developed left-sided colon cancer. Left-sided colon cancer occurred slightly more often in whites (59.4%) than in blacks (56%).

Right-sided colon cancer was more likely to have reached an advanced stage prior to diagnosis; 60.84% of cases were diagnosed as stage II-IV. In left-sided colon cancer, by contrast, nearly half of cases (48.2%) were stage I at diagnosis.

Notably, right-sided colon cancer has a worse one-year survival rate than left-sided colon cancer. The majority of patients with right-sided colon cancer (50.5%) died within the first year after diagnosis compared to 42.2% of those with left-sided colon cancer.


1Azar I, Esfandiarifard S, Virk G, et al. Primary tumor sidedness in colorectal cancer at VA hospitals: A nation-wide study. J Clin Oncol 36, 2018 (suppl; abstr e15638).

Related Articles

VA/National Cancer Institute Partnership Increases Veteran Access to Trials

Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.

VA Continues Hepatocellular Screening, but Study Questions the Value

Although a recent study determined that screening veterans with cirrhosis for hepatocellular carcinoma did not reduce the risk of death associated with liver cancer, the VA has no plans to change its screening practices.


U.S. Medicine Recommends


More From oncology

Oncology

VA/National Cancer Institute Partnership Increases Veteran Access to Trials

Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.

Oncology

VA Continues Hepatocellular Screening, but Study Questions the Value

Although a recent study determined that screening veterans with cirrhosis for hepatocellular carcinoma did not reduce the risk of death associated with liver cancer, the VA has no plans to change its screening practices.

Oncology

Testosterone Therapy Not Linked to Aggressive Prostate Cancer in Veterans

Clinicians prescribing supplemental testosterone in men with low levels always have a nagging concern about the possible link between increasing hormone levels and prostate cancer.

Oncology

Side-effects Differ Between Radiation Therapies for Prostate Cancer

A recent study compared patient-reported disease-specific functional outcomes after external beam radiation therapy (EBRT) and EBRT combined with low-dose-rate brachytherapy prostate boost (EB-LDR) among men with localized prostate cancer.

Oncology

Parkinson's Drug Not Associated With Higher Prostate Cancer Risk

An increased incidence of prostate cancer was observed in Parkinson's disease (PD) patients treated with entacapone during a pre-approval randomized clinical trial, according to a new study which noted that the relationship had not yet been intensely investigated.

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up